Start your intake How Semaglutide Works for Weight Loss and Metabolic Health Semaglutide belongs to a class of medications called GLP-1 receptor agonists, originally developed to manage type 2 diabetes
Wegovy was designed and studied for continued use at therapeutic doses typically 1.7 mg or 2.4 mg weekly, and now up to 7.2 mg weekly under the Wegovy HD approval (March 2026)
The more recent REDUCE-IT trial (n = 8,179) found that 4 g/day of icosapent ethyl (a purified eicosapentaenoic acid ethyl ester) significantly reduced cardiovascular death (HR 0.75, 95% CI 0.680.83), myocardial infarction, and stroke in high-risk individuals with elevated triglycerides despite statin therapy
Phase 2 (Weeks 5-8): Add a second peptide while continuing the first one, while initially using separate injection sites for each peptide
GHK-Cu is a known promoter of angiogenesis the creation of new micro-vessels
Kopec AK, Abrahams SR, Thornton S, Palumbo JS, Mullins ES, Divanovic S, Weiler H, Owens AP 3rd, Mackman N, Goss A, van Ryn J, Luyendyk JP, Flick MJ (2017) Thrombin promotes diet-induced obesity through fibrin-driven inflammation
